Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Accumulated Expenses (2023 - 2025)

Verrica Pharmaceuticals has reported Other Accumulated Expenses over the past 3 years, most recently at $366000.0 for Q2 2025.

  • Quarterly results put Other Accumulated Expenses at $366000.0 for Q2 2025, up 21.59% from a year ago — trailing twelve months through Jun 2025 was $366000.0 (up 21.59% YoY), and the annual figure for FY2024 was $105000.0, down 56.97%.
  • Other Accumulated Expenses for Q2 2025 was $366000.0 at Verrica Pharmaceuticals, up from $166000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VRCA hit a ceiling of $428000.0 in Q3 2024 and a floor of $105000.0 in Q4 2024.
  • Median Other Accumulated Expenses over the past 3 years was $291500.0 (2023), compared with a mean of $276625.0.
  • Peak annual rise in Other Accumulated Expenses hit 51.77% in 2024, while the deepest fall reached 56.97% in 2024.
  • Verrica Pharmaceuticals' Other Accumulated Expenses stood at $244000.0 in 2023, then tumbled by 56.97% to $105000.0 in 2024, then soared by 248.57% to $366000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $366000.0 (Q2 2025), $166000.0 (Q1 2025), and $105000.0 (Q4 2024) per Business Quant data.